nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

11.07.2022 | comment

Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities

verfasst von: Andreas Pircher, MD PhD, Roberto N. Miranda

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Excerpt

In this issue of MEMO, Ghindinelli et al. [1] report on a rare case of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) including a review of the literature. The authors report on an interesting case of a patient with several breast reconstructive operations following thoracic trauma including implantation of breast implants, which led to development of a BIA-ALCL and, finally, successful surgical removal. Although the case report leaves several questions on current recommendations for management, it highlights the multidisciplinary management of the disease starting from diagnostic work-up until standard follow-up visits. …

Vorheriger Artikel Breast implant-associated anaplastic large-cell lymphoma: a European case report and literature review

Nächster Artikel Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021

Ghidinelli F, Filippini L, Porsio P, Canzi F, Balzano R, Flocchini E, et al. Breast implant-associated anaplastic large-cell lymphoma: a European case report and literature review. Memo. 2021. https://doi.org/10.1007/s12254-021-00714-4CrossRef

Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthet Surg J. 2019;39(Suppl_1):S3–S13.CrossRef

Nelson JA, McCarthy C, Dabic S, Polanco T, Chilov M, Mehrara BJ, et al. BIA-ALCL and textured breast implants: a systematic review of evidence supporting surgical risk management strategies. Plast Reconstr Surg. 2021;147(5S):7S–13S.CrossRef

Wang Y, Zhang Q, Tan Y, Lv W, Zhao C, Xiong M, et al. Current progress in breast implant-associated anaplastic large cell lymphoma. Front Oncol. 2021;11:785887.CrossRef

Ferrufino-Schmidt MC, Medeiros LJ, Liu H, Clemens MW, Hunt KK, Laurent C, et al. Clinicopathologic features and prognostic impact of lymph node involvement in patients with breast implant-associated anaplastic large cell lymphoma. Am J Surg Pathol. 2018;42(3):293–305.CrossRef

Walker JN, Hanson BM, Pinkner CL, Simar SR, Pinkner JS, Parikh R, et al. Insights into the microbiome of breast implants and Periprosthetic tissue in breast implant-associated anaplastic large cell lymphoma. Sci Rep. 2019;9(1):10393.CrossRef

DeCoster RC, Lynch EB, Bonaroti AR, Webster JM, Butterfield TA, Evers BM, et al. Breast implant-associated anaplastic large cell lymphoma: an evidence-based systematic review. Ann Surg. 2021;273(3):449–58.CrossRef

Titel: Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities
verfasst von: Andreas Pircher, MD PhD
Roberto N. Miranda
Publikationsdatum: 11.07.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-022-00821-w

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Applicability of ESMO-MCBS and ESCAT for molecular tumor boards

Neoadjuvant treatment in non-small-cell lung cancer—the earlier, the better

Breast implant-associated anaplastic large-cell lymphoma: a European case report and literature review

Multiple myeloma with central nervous system relapse: a case report

Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021

Real time experience applying CAR T-cells for B-cell lymphoma—What we have learned so far: Acute toxicity management